• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

immune thrombocytopenia (ITP) - Articles and news items

fostamatinib-successful

Rigel’s fostamatinib successfully meets endpoint in chronic ITP trial

Industry news / 30 August 2016 / Niamh Louise Marriott, Digital Content Producer

The study (n=76) showed that 18% of patients receiving fostamatinib achieved a stable platelet response compared to none receiving a placebo control (p=0.0261)…

Revolade

Long-term safety data for Revolade in adults with chronic ITP

Industry news / 10 June 2016 / Victoria White, Digital Content Producer

Data from the largest study of its kind confirm the long-term safety profile of Novartis’ Revolade in adults with chronic immune thrombocytopenia…

itp

Amgen’s Nplate shows significant increase in durable platelet response in ITP

Industry news / 21 April 2016 / Victoria White, Digital Content Producer

A Phase III study shows that 52 percent of Nplate patients achieved a durable platelet response, compared with 10 percent of placebo-treated patients…

Revolade

EU approval for Revolade for paediatric patients with chronic ITP

Industry news / 7 April 2016 / Victoria White

The approval includes the use of a new oral suspension formulation of Revolade designed for younger children who may not be able to swallow tablets…

Eltrombopag

Eltrombopag shown to be effective in children with ITP

Industry news / 9 October 2015 / Victoria White

The study demonstrate that eltrombopag is well tolerated and effective, consistently stabilising the platelet count to over 50 X 109 per litre within 2-6 weeks for 40% of children…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +